BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar

Completed

Conditions: Carcinoma, Renal Cell
Carcinoma, Renal Cell (Advanced)

Interventions: Drug: Nexavar (Sorafenib, BAY43-9006)

First Posted Date: 2009-05-08

Last Posted Date: 2010-09-30

Lead Sponsor: Bayer

Target Recruit Count: 2840

Registration Number: NCT00895674

BEYOND Pilot Study

Phase 2

Completed

Conditions: Multiple Sclerosis
Relapsing-Remitting

Interventions: Drug: Betaseron (Interferon beta-1b, BAY86-5046)

First Posted Date: 2009-05-05

Last Posted Date: 2009-11-09

Lead Sponsor: Bayer

Target Recruit Count: 71

Registration Number: NCT00893217

Comparative Safety Study of New Sinecort Formulation Versus Positive Control

Phase 1

Completed

Conditions: Healthy

Interventions: Device: Untreated skin under application chamber
Drug: Dexpanthenol (Sinecort, BAY81-2996)
Drug: Positive control, Na-laurylsulfat-solution

First Posted Date: 2009-04-22

Last Posted Date: 2014-06-23

Lead Sponsor: Bayer

Target Recruit Count: 33

Registration Number: NCT00885937

Mirena Observational Program

Completed

Conditions: Contraception
Endometrial Hyperplasia
Estrogen Replacement Therapy
Menorrhagia

Interventions: Drug: Levonorgestrel (Mirena, BAY86-5028)

First Posted Date: 2009-04-20

Last Posted Date: 2016-09-30

Lead Sponsor: Bayer

Target Recruit Count: 2725

Registration Number: NCT00883662

GA Levonorgestrel Intrauterine Contraceptive System (LCS) Phase III Study China

Phase 3

Completed

Conditions: Contraception

Interventions: Drug: Levonorgestrel IUS (LCS, BAY86-5028)

First Posted Date: 2009-04-20

Last Posted Date: 2014-08-21

Lead Sponsor: Bayer

Target Recruit Count: 918

Registration Number: NCT00884260

Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)

Completed

Conditions: Primary Hypertension

Interventions: Drug: Ventavis (Iloprost, BAYQ6256)

First Posted Date: 2009-04-17

Last Posted Date: 2009-04-17

Lead Sponsor: Bayer

Target Recruit Count: 38

Registration Number: NCT00882947

Physical Activity and Fatigue in Early Multiple Sclerosis (MS)

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Interferon beta-1b (Betaseron, BAY86-5046)

First Posted Date: 2009-04-16

Last Posted Date: 2012-05-30

Lead Sponsor: Bayer

Target Recruit Count: 1739

Registration Number: NCT00882453

SYMPROVE III: Health Services Research Study for Treatment of the Moderate and Severe Acute Exacerbations of Chronic Bronchitis (AECB)

Completed

Conditions: Chronic Bronchitis

Interventions: Drug: Moxifloxacin (Avelox, BAY12-8039)

First Posted Date: 2009-04-09

Last Posted Date: 2014-06-23

Lead Sponsor: Bayer

Target Recruit Count: 345

Registration Number: NCT00879008

VICTOR - Avelox® Intravenous (i.v.) in Acute Exacerbations of Chronic Bronchitis

Completed

Conditions: Chronic Bronchitis
Disease Exacerbation

Interventions: Drug: Moxifloxacin (Avelox, BAY12-8039)

First Posted Date: 2009-04-06

Last Posted Date: 2012-09-10

Lead Sponsor: Bayer

Target Recruit Count: 1206

Registration Number: NCT00876577

PMS Study Ultravist-IMAGE, IoproMide (UltrAvist) to Gain Further Information on Tolerability and Safety in X-ray Examination

Completed

Conditions: Diagnostic Imaging

Interventions: Drug: Ultravist (Iopromide, BAY86-4877)

First Posted Date: 2009-04-06

Last Posted Date: 2011-02-28

Lead Sponsor: Bayer

Target Recruit Count: 44920

Registration Number: NCT00876083

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy